Screener
SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Cost of license, services, and royalty revenue | 2,207 | 605 |
| Total cost of revenues | 9,939 | 2,639 |
| Research and development | 126,636 | 111,431 |
| Selling, general and administrative | 163,896 | 106,365 |
| Restructuring, impairment, and related charges | — | 570 |
| Total operating costs and expenses | 300,471 | 221,005 |
| Loss from operations | (105,956) | (104,372) |
| Other income (expense), net: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's SG&A?
- BridgeBio Pharma (BBIO) reported SG&A of $163.9M in Q1 2026.
- How has BridgeBio Pharma's SG&A changed year-over-year?
- BridgeBio Pharma's SG&A increased by 54.1% year-over-year, from $106.37M to $163.9M.
- What is the long-term trend for BridgeBio Pharma's SG&A?
- Over 4 years (2021 to 2025), BridgeBio Pharma's SG&A has grown at a 28.9% compound annual growth rate (CAGR), from $192.21M to $531.23M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about BridgeBio Pharma's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude